ArticleBMC medical ethics2025
Ethical challenges in biomarker research and precision medicine - a qualitative study in dermatology.
Article in BMC medical ethics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Next-generation smart polymeric hydrogels for chronic wound management: integrating antimicrobial, immunomodulatory and regenerative strategies.RSC advances · 2026Review
- The Concept of Harm in Medical Ethics.Bioethics · 2026Article
- Integrating Artificial Intelligence with Global Genomic Resources: A Narrative Review of Implications for Precision Medicine.Journal of multidisciplinary healthcare · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundOver 300 million individuals worldwide live with Atopic Dermatitis and Psoriasis, which are among the most common chronic inflammatory skin diseases. Multimodal biomarkers are currently being developed using large-scale data and artificial intelligence to allow for more targeted prediction and to improve treatment of patients with Atopic Dermatitis/Psoriasis. Although this promises enormous benefits for patients, it comes with critical challenges. This article offers an in-depth analysis of the ethical challenges in research and application of data-driven biomarkers in chronic inflammatory skin disease, which, as recent work shows, has not yet been explored in depth.
methodsWe conducted an interview study with 28 members of the BIOMarkers in Atopic Dermatitis and Psoriasis consortium including multiple stakeholder groups involved in biomarker research and application following the COREQ checklist. The interviews were analysed and interpreted theme-oriented using an updated grounded theory approach.
resultsThe interviews revealed interconnected ethical challenges described by a wide range of stakeholders involved in biomarker research. Our analysis identified two broad categories of ethical challenges - disease-related and biomarker-related issues - from which three cross-cutting themes emerged: multiple forms of harm, multiple injustices, and multiple uncertainties. Disease-related challenges include covert psycho-socio-physical dimensions of harm and suffering in Atopic Dermatitis/Psoriasis, quality of life impacts, trial-and-error approaches, and communication and expectation management in clinical practice. Biomarker-related challenges range from big data use with multiple biases in the different data-sets, stratification of patients into subgroups, to invasiveness of diagnostic measures, multiple uncertainties and expectation management in science. This article also provides stakeholder suggestions for mitigating harm associated with Atopic Dermatitis/Psoriasis and biomarker use to inform policy development.
conclusionsThe identification of the many ethical challenges uncovered in the interviews and the nuanced view of harm, intersecting injustices including epistemic injustice, and the multiple uncertainties provide crucial considerations for evaluating the risks and benefits of biomarker research and application in healthcare. These insights should inform policy development for data/AI-driven biomarker use for Atopic Dermatitis/Psoriasis and support research practice, public health interventions, and clinical practice to develop and apply medical innovations that are ethically responsible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.